Abstract: The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the effector portion comprises or consists of interleukin-12, or a functional fragment or variant thereof, characterized in the monoclonal antibody having specificity for oncofoetal fibronectin binds to a region of oncofoetal fibronectin other than the ED-B region. The invention further provides nucleic acids encoding the compounds of the invention, and the use of such compounds in medicine, e.g. in the treatment of cancer.
Type:
Grant
Filed:
January 5, 2005
Date of Patent:
April 16, 2013
Assignees:
Antisoma Research Limited, EMD Serono Research Center, Inc.
Inventors:
Stephen Gillies, Kin-Ming Lo, Yan Lan, Rakesh Verma
Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic; hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
Type:
Application
Filed:
October 31, 2007
Publication date:
July 21, 2011
Applicant:
Antisoma Research Limited
Inventors:
John O. Trent, Paula J. Bates, Donald M. Miller
Abstract: The present invention relates to pharmaceutically stable crystalline forms of (5,6-Dimethyl-9-oxo-9H-xanthene-4-yl)acetic acid (DMXAA) sodium salt, processes for preparing those stable crystalline forms; pharmaceutical compositions comprising at least one of those crystalline forms in solid form or in dissolved form and a pharmaceutically acceptable carrier. Disclosed are methods of using those pharmaceutical compositions to treat tumours, optionally in combination with other active pharmaceutical agents.
Abstract: The present invention relates to compositions, methods, and kits for modulating tumor proliferation using G-rich oligonucleotides and one or more chemotherapeutic agents.
Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
Type:
Application
Filed:
October 31, 2007
Publication date:
December 25, 2008
Applicant:
Antisoma Research Limited
Inventors:
John O. Trent, Paula J. Bates, Donald M. Miller
Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
Type:
Application
Filed:
October 31, 2007
Publication date:
December 25, 2008
Applicant:
Antisoma Research Limited
Inventors:
John O. Trent, Paula J. Bates, Donald M. Miller
Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
Type:
Application
Filed:
October 31, 2007
Publication date:
December 25, 2008
Applicant:
Antisoma Research Limited
Inventors:
John O. Trent, Paula J. Bates, Donald M. Miller
Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
Type:
Application
Filed:
October 31, 2007
Publication date:
December 25, 2008
Applicant:
Antisoma Research Limited
Inventors:
John O. Trent, Paula J. Bates, Donald M. Miller
Abstract: The present invention provides a method for inhibiting the proliferation of malignant and/or hyperplastic cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich oligonucleotide. The present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein which is nucleolin and/or nucleolin-like in nature, which is implicated in the proliferation of cells, specifically malignant and/or hyperplastic cells, and a method for their selection.
Type:
Grant
Filed:
April 7, 2000
Date of Patent:
January 1, 2008
Assignee:
Antisoma Research Limited
Inventors:
Donald M. Miller, Paula J. Bates, John O. Trent
Abstract: Radioactively labeled peptides comprising oligopeptides of from 3 to 10 peptide units and containing the sequence RGD and particularly the oligopeptides RGDSY and RGDFY, are disclosed as in vivo thrombus, tumor or CAM markers for the in vivo diagnosis and detection of thrombi, tumors or CAM in mammals.
Abstract: Radioactively labelled peptides comprising oligopeptides of from 3 to 10 peptide units and containing the sequence RGD and particularly the oligopeptides RGDSY and RGDFY, are disclosed as in vivo thrombus, tumour or CAM markers for the in vivo diagnosis and detection or thrombi, tumours or CAM in mammals.